Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05861102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

StatusCompleted
PhasePhase 3
Started2023-07-20
View on ClinicalTrials.gov ↗

Amendment history

2026-09-23
Trial completed
Primary completion confirmed: June 2025 (last estimated May 2026)
2025-12-30
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-05→2026-05
Completion date2025-07→2026-07
Enrollment targetestimated 258→confirmed 265
Study sitesdetails revised at 1 of 1 site
2024-12-11
Study Status v3
Re-verified, no change to tracked fields
2023-07-24
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-09→confirmed 2023-07-20
Study sitesdetails revised at 1 of 1 site
2023-07-10
Study Status v1
Start date2023-05→2023-09
2023-05-06
Original filing
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).
Trial Details
NCT Number NCT05861102
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Ankylosing Spondylitis
Enrollment 265 participants
Start Date 2023-07-20
Primary Completion 2025-06-09 (estimated)
Study Completion 2025-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-22